Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SWX:KOMN
SWX:KOMNMachinery

3 European Stocks Possibly Trading At Up To 40.3% Below Intrinsic Value

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keenly observing opportunities for undervalued stocks amidst mixed performances across major indices. In this context, identifying stocks trading below their intrinsic value can be a strategic move for those looking to capitalize on potential market inefficiencies.
ENXTPA:HCO
ENXTPA:HCOMedia

European Penny Stocks To Watch In January 2026

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keeping a close watch on smaller companies that might offer unique opportunities. Penny stocks, despite their somewhat outdated name, remain an intriguing area of investment for those interested in potentially high-growth sectors. These stocks often represent smaller or newer companies that can provide a blend of affordability and growth...
XTRA:FNTN
XTRA:FNTNWireless Telecom

European Dividend Stocks To Consider In January 2026

As we enter January 2026, the European markets are showing resilience, with the pan-European STOXX Europe 600 Index ending higher amid positive economic data and earnings results. In this environment of cautious optimism, investors may find dividend stocks appealing due to their potential for stable income and capital preservation during mixed market conditions.
NasdaqGS:VIR
NasdaqGS:VIRBiotechs

A Look At Vir Biotechnology (VIR) Valuation After New SOLSTICE Trial Data And Pipeline Updates

Why Vir Biotechnology’s latest clinical data matters for investors Vir Biotechnology (VIR) recently reported new positive data from its SOLSTICE Phase 2 trial in chronic hepatitis delta, highlighting stronger and more sustained hepatitis delta virus RNA suppression for its tobevibart and elebsiran combination through 96 weeks. The company also used the 44th Annual J.P. Morgan Healthcare Conference to outline broader clinical plans, including the ECLIPSE Phase 3 program in hepatitis delta and...
NYSE:WWW
NYSE:WWWLuxury

Assessing Wolverine World Wide (WWW) Valuation After Recent Share Price Swings

Event-driven snapshot of Wolverine World Wide Wolverine World Wide (WWW) has drawn investor attention after recent share price swings, with the stock up around 10% over the past month but showing a decline across the past 3 months. See our latest analysis for Wolverine World Wide. At a share price of $19.28, Wolverine World Wide’s recent 10.05% 1 month share price return contrasts with its 26.24% 3 month share price decline and a 12.41% 1 year total shareholder return loss, suggesting...
ASX:SVM
ASX:SVMMetals and Mining

Assessing Sovereign Metals' Valuation After Kasiya Rare Earth Tailings Breakthrough

Why the Kasiya rare earths update matters for Sovereign Metals (ASX:SVM) Sovereign Metals (ASX:SVM) has drawn fresh attention after confirming it can recover high-value heavy rare earths from tailings at its Kasiya project, effectively adding a third critical mineral stream. For you as an investor, this kind of development changes how Kasiya is framed. It shifts the project from a rutile and graphite story into a broader critical materials project tied to advanced technology supply...
TSE:8439
TSE:8439Diversified Financial

Assessing Tokyo Century (TSE:8439) Valuation After A Strong Multi‑Period Share Price Run

Context for Tokyo Century’s Recent Share Moves Tokyo Century (TSE:8439) has attracted fresh attention after a strong run, with the share price recording gains over the past week, month, and past 3 months, putting recent performance into clearer focus for investors. See our latest analysis for Tokyo Century. At a share price of ¥2,166.5, Tokyo Century’s momentum looks solid, with a 30-day share price return of 6.57% and a 90-day gain of 16.29%, alongside a 1-year total shareholder return of...